It's Time to Abandon an Upper Limit of Normal for Prostate Specific Antigen: Assessing the Risk of Prostate Cancer

Journal of Urology

Volumn 180, Issue 4, 2008, Pages 1219-1222

  Thompson, Ian M ^a   Ankerst, Donna P ^a   Etzioni, Ruth ^b   Wang, Thomas ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DIGITAL RECTAL EXAMINATION; EDITORIAL; GLEASON SCORE; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

BIOPSY, NEEDLE; DECISION MAKING; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; UNITED STATES;

EID: 50949089297     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.07.089     Document Type: Editorial

References (28)

1. Ablin R.J., Soanes W.A., Bronson P., and Witebsky E. Precipitating antigens of the normal human prostate. J Reprod Fertil 22 (1970) 573
2. Hudson M., Bahnson R., and Catalona W. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142 (1989) 1011
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43
4. Gohagan J.K., Prorok P.C., Hayes R.B., and Kramer B.S. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21 (2000) 251S
5. Postma R., Schröder F.H., van Leenders G.J., Hoedemaeker R.F., Vis A.N., Roobol M.J., et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam. A comparison of two rounds of screening. Eur Urol 52 (2007) 89
6. Catalona W., Smith D., Ratliff T., Dodds K.M., Coplen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156
7. Cooner W.H., Mosley B.R., Rutherford C.L., Beard J.H., Pond H.S., Terry W.J., et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143 (1990) 1146
8. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277 (1997) 1452
9. Gann P.H., Hennekens C.H., and Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 (1995) 289
10. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
11. Thompson I.M., Ankerst D.P., Chi C., Lucia M.S., Goodman P.J., Crowley J.J., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66
12. Albano J.D., Ward E., Jemal A., Anderson R., Cokkinides V.E., Murray T., et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst 99 (2007) 1384
13. Haas G.P., Delongchamps N.B., Jones R.F., Chandan V., Serio A.M., Vickers A.J., et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 99 (2007) 1484
14. Giovannucci E., Liu Y., Platz E.A., Stampfer M.J., and Willett W.C. Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-Up Study. Int J Cancer 121 (2007) 1571
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection. V.2.2007. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree#detection Accessed March 30, 2008.
16. Keetch D.W., and Catalona W.J. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol 154 (1995) 1795
17. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529
18. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof#moreinfo Accessed October 12, 2007.
19. Parekh D.J., Ankerst D.P., Higgins B.A., Hernandez J., Canby-Hagino E., Brand T., et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 68 (2006) 1152
20. Hernandez D.J., Han M., Humphreys E.B., Mangold L.A., Brawer M.K., Taneja S.S., et al. External validation of the prostate cancer risk calculator. J Urol 177 suppl (2007) 622 abstract 1874
21. Han M., Humphreys E.B., Hernandez D.J., Partin A.W., Roehl K.A., and Catalona W.J. Comparison between the prostate cancer risk calculator and serum PSA. J Urol 177 suppl (2007) 624 abstract 1875
22. Oesterling J.E., Cooner W.H., Jacobsen S.J., Guess H.A., and Lieber M.M. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am 20 (1993) 671
23. Ries L.A.G., Melbert D., Krapcho M., Mariotto A., Miller B.A., Feuer E.J., et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute, Bethesda, Maryland. http://seer.cancer.gov/csr/1975_2004 Accessed June 18, 2008.
24. American Cancer Society Guidelines for the Early Detection of Cancer. http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp?sitearea=PED Accessed March 30, 2008.
25. Lucia M.S., Darke A.L., Goodman P.J., LaRosa F.G., Parnes H.L., Ford L.G., et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prevent Res 2008; Online First 2008. http://cancerpreventionresearch.aacrjournals.org/cgi/rapidpdf/1940-6207.CAPR-08-0078v1 Accessed June 18, 2008.
26. Epstein J.I., Sanderson H., Carter H.B., and Scharfstein D.O. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 66 (2005) 356
27. Albertsen P.C., Hanley J.A., and Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095
28. Klotz L. Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?. Curr Urol Rep 8 (2007) 341